Neurovascular coupling in Parkinson's disease patients: Effects of dementia and acetylcholinesterase inhibitor treatment

Journal of Alzheimer's Disease

Volumn 22, Issue 2, 2010, Pages 415-421

  Rosengarten, Bernhard ^a   Dannhardt, Veren ^a   Burr, Ole ^a   Pöhler, Matthias ^a   Rosengarten, Susanne ^a   Oechsner, Matthias ^b   Reuter, Iris ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b Parkinson Clinic   (Germany)

Author keywords

Alzheimer's disease; cerebral blood flow; dementia; functional activation; neurovascular coupling; Parkinson's disease; visually evoked potential

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; DOPPLER FLOWMETRY; ELECTROENCEPHALOGRAPHY; ENZYME ACTIVITY; EVOKED VISUAL RESPONSE; EXCITATION CONTRACTION COUPLING; FEMALE; FLOW RATE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROVASCULAR COUPLING; PARKINSON DISEASE; POSTERIOR CEREBRAL ARTERY; PRIORITY JOURNAL; VISUAL STIMULATION;

EID: 78650831988     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101140     Document Type: Article

References (47)

1. Farlow MR, Cummings J (2008) A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dement Geriatr Cogn Disord 25, 301-308.
2. Aarsland D, Beyer MK, Kurz MW (2008) Dementia in Parkinson's disease. Curr Opin Neurol 21, 676-682.
3. Whitehouse PJ, Hedreen JC, White CL, 3rd, Price DL (1983) Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13, 243-248.
4. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS (1982) The cholin-ergic hypothesis of geriatric memory dysfunction. Science 217, 408-414.
5. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in parkinso-nian dementia than in Alzheimer disease: an in vivo positron emission tomographic study Arch Neurol 60, 1745-1748.
6. Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, Ota T, Asahina M, Fukushi K, Kuwabara S, Hattori T, Suhara T, Irie T (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET Neurology 73, 273278.
7. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD (2005) Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65, 1716-1722.
8. Manganelli F, Vitale C, Santangelo G, Pisciotta C, Iodice R, Cozzolino A, Dubbioso R, Picillo M, Barone P, Santoro L (2009) Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain 132, 2350-2355.
9. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 21, 1899-1907.
10. Emre M (2004) Dementia in Parkinson's disease: cause and treatment. Curr Opin Neurol 17, 399-404.
11. Muller T, Welnic J, Fuchs G, Baas H, Ebersbach G, Reich-mann H (2006) The DONPAD-study-treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl, 27-30.
12. Rosengarten B, Paulsen S, Burr O, Kaps M (2008) Neurovas-cular coupling in Alzheimer patients: Effect of acetylcholine-esterase inhibitors. Neurobiol Aging 30, 1918-1923.
13. Becker-Barroso E (2005) More support for vascular basis of Alzheimer's disease. Lancet Neurol 4, 598-599.
14. de la Torre JC, Stefano GB (2000) Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev 34, 119-136.
15. Rosengarten B, Paulsen S, Molnar S, Kaschel R, Gallhofer B, Kaps M (2006) Acetylcholine esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimer patients. J Neurol 253, 58-64.
16. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5, 347360.
17. Hamel E (2004) Cholinergic modulation of the cortical mi-crovascular bed. Prog Brain Res 145, 171-178.
18. Toda N, Ayajiki K, Okamura T (2009) Cerebral blood flow regulation by nitric oxide in neurological disorders. Can J Physiol Pharmacol 87, 581-594.
19. Kitaura H, Uozumi N, Tohmi M, Yamazaki M, Sakimura K, Kudoh M, Shimizu T, Shibuki K (2007) Roles of nitric oxide as a vasodilator in neurovascular coupling of mouse so-matosensory cortex. Neurosci Res 59, 160-171.
20. Rosengarten B, Paulsen S, Burr O, Kaps M (2009) Neurovas-cular coupling in Alzheimer patients: effect of acetylcholine-esterase inhibitors. Neurobiol Aging 30, 1918-1923.
21. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181-184.
22. Kulasingam SL, Samsa GP, Zarin DA, Rutschmann OT, Pat-wardhan MB, McCrory DC, Schmechel DE, Matchar DB (2003) When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis. Value Health 6, 542-550.
23. Kapeller P, Barber R, Vermeulen RJ, Ader H, Scheltens P, Freidl W, Almkvist O, Moretti M, del Ser T, Vaghfeldt P, Enzinger C, Barkhof F, Inzitari D, Erkinjunti T, Schmidt R, Fazekas F (2003) Visual rating of age-related white matter changes on magnetic resonance imaging. Stroke 34, 441-445.
24. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17, 427-442.
25. Schwab RS, EAJ, Projection techniques for evaluating surgery in Parkinson's Disease, in 3rd Symposium on Parkinson's Disease, Royal College of Surgeons in Edinburgh, May 20-22, p. 152-157.
26. Rosengarten B, Aldinger C, Kaufmann A, Kaps M (2001) Comparison of visually evoked peak systolic and end diastolic blood flow velocity using a control system approach. Ultrasound Med Biol 27, 1499-1503.
27. Rosengarten B, Huwendiek O, Kaps M (2001) Neurovascular coupling and cerebral autoregulation can be described in terms of a control system. Ultrasound Med Biol 27, 189-193.
28. Afra J, Cecchini AP, De Pasqua V, Albert A, Schoenen J (1998) Visual evoked potentials during long periods ofpattern-reversal stimulation in migraine. Brain 121 (Pt 2), 233-241.
29. Conner JM, Chiba AA, Tuszynski MH (2005) The basal forebrain cholinergic system is essential for cortical plasticity and functional recovery following brain injury. Neuron 46, 173179.
30. Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen JP (2005) The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurol Scand 112, 386-390.
31. Nanhoe-Mahabier W, de Laat KF, Visser JE, Zijlmans J, de Leeuw FE, Bloem BR (2009) Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol 5, 533-541.
32. Deschaintre Y, Richard F, Leys D, Pasquier F (2009) Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73, 674-680.
33. Qiu C, Kivipelto M, von Strauss E (2009) Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11, 111-128.
34. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE, Greenberg SM (2009) Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 72, 1230-1235.
35. Tong XK, Nicolakakis N, Kocharyan A, Hamel E (2005) Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J Neurosci 25, 11165-11174.
36. Jellinger KA (2010) Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases. Neurodegener Disord 7, 112-115.
37. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA (2008). Neurology 71, 903-910.
38. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D (2009). Neurobiol Dis 34, 107-112.
39. Jellinger KA, Attems J (2010) Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 119, 421-433.
40. Miller RL, James-Kracke M, Sun GY, Sun AY (2009) Oxida-tive and inflammatory pathways in Parkinson's disease. Neu-rochem Res 34, 55-65.
41. Jellinger KA (2009) Recent advances in our understanding of neurodegeneration. J Neural Transm 116, 1111-1162.
42. Olivares D, Huang X, Branden L, Greig NH, Rogers JT (2009) Physiological and Pathological Role of Alpha-synuclein in Parkinson's Disease Through Iron Mediated Oxidative Stress; The Role of a Putative Iron-responsive Element. Int J Mol Sci 10, 1226-1260.
43. Rosengarten B, Aldinger C, Kaufmann A, Kaps M (2002) Neurovascular coupling remains unaffected by glyceryl trinitrate. Cerebrovasc Dis 14, 58-60.
44. Olah L, Raiter Y, Candale C, Molnar S, Rosengarten B, Born-stein NM, Csiba L (2008) Visually evoked cerebral vasomotor response in smoking and nonsmoking young adults, investigated by functional transcranial Doppler. Nicotine Tob Res 10, 353-358.
45. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE (1993) Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88, 2149-2155.
46. Zhao J, He X, Liu Z, Yang D (2006) The effects of clozapine on cognitive function and regional cerebral blood flow in the negative symptom profile schizophrenia. Int J Psychiatry Med 36, 171-181.
47. Goldman RG, Alexander GE, Zemishlany Z, Mukherjee S, Sackeim H, Prohovnik I (1996) Acute effects of haloperidol on cerebral cortex blood flow in normal and schizophrenic subjects. Biol Psychiatry 40, 604-608.